Samuel B. Ho
VA San Diego Healthcare System
3350 La Jolla Village Drive
San Diego
CA 92161
USA
Name/email consistency: high
- U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Ho, S.B., Aqel, B., Dieperink, E., Liu, S., Tetrick, L., Falck-Ytter, Y., DeComarmond, C., Smith, C.I., McKee, D.P., Boyd, W., Kulig, C.C., Bini, E.J., Pedrosa, M.C. Dig. Dis. Sci. (2011)
- Cost-effectiveness of a mailed educational reminder to increase colorectal cancer screening. Lee, J.K., Groessl, E.J., Ganiats, T.G., Ho, S.B. BMC. Gastroenterol (2011)
- Activity of recombinant cysteine-rich domain proteins derived from the membrane-bound MUC17/Muc3 family mucins. Ho, S.B., Luu, Y., Shekels, L.L., Batra, S.K., Kandarian, B., Evans, D.B., Zaworski, P.G., Wolfe, C.L., Heinrikson, R.L. Biochim. Biophys. Acta (2010)
- Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Ho, S.B., Dvorak, L.A., Moor, R.E., Jacobson, A.C., Frey, M.R., Corredor, J., Polk, D.B., Shekels, L.L. Gastroenterology (2006)